New US Food and Drug Administration Commissioner Margaret Hamburg revealed at the start of this month that a task force has been established to develop recommendations for enhancing the transparency of the organization's operations and decision-making process, with the aim of creating greater openness.
To support the efforts of the task force, the FDA issued a Federal Register notice announcing a June 24 public meeting to solicit recommendations on how the agency can make useful and understandable information on its activities and decisions more available.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze